

LETTER OPEN



MYELODYSPLASTIC NEOPLASM

Mutations in the splicing factor *SF3B1* are linked to frequent emergence of HLA-DR^{low/neg} monocytes in lower-risk myelodysplastic neoplasms

Susann Winter^{1,16}, Marie Schneider^{2,16}, Uta Oelschlaegel¹, Giulia Maggioni^{3,4}, Elena Riva^{3,4}, Marco Gabriele Raddi⁵, Sara Bencini⁶, Benedetta Peruzzi⁶, Desmond Choy³, Rita Antunes Dos Reis³, Esther Güse^{7,8}, Christopher Lischer^{7,8}, Julio Vera^{7,8}, Jessica A. Timms³, Nicolas Sompairac³, Katja Sockel¹, Antonella Poloni⁹, Antje Tunger^{10,11}, Matteo Giovanni Della Porta^{4,12}, Valeria Santini⁵, Marc Schmitz^{10,11,13}, Uwe Platzbecker^{12,13,14,16} and Shahram Kordasti^{3,9,15,16}✉

© The Author(s) 2024

Leukemia; <https://doi.org/10.1038/s41375-024-02249-z>

TO THE EDITOR:

Somatic mutations in the splicing factor *SF3B1* occur in about one-third of all myelodysplastic neoplasms (MDS) and define a subgroup of patients characterized by ring sideroblasts (RS), ineffective erythropoiesis, and an indolent disease course in lower-risk (LR) MDS [1]. They are typically heterozygous missense substitutions, most commonly (>50% in MDS) involving p.K700E (*SF3B1* NM_012433.4: c.2098A>G (p.Lys700Glu), hereafter referred to as *SF3B1*^{K700E}), and have been shown to induce mis-splicing of key genes throughout erythroid differentiation [2, 3]. Surprisingly, although *SF3B1* mutations are known to target multipotent lymphomyeloid hematopoietic stem cells and clonally propagate to myeloid progenitors [4], their impact on mature immune cells remains largely unexplored. Clinically, *SF3B1* mutations are associated with high response rates to the erythroid maturation agent luspatercept and lower response to immunosuppressive treatment (IST) [5–7].

In this study, we performed multiplex immunophenotyping in conjunction with machine learning-based analytical approaches on bone marrow (BM)/peripheral blood (PB) samples from newly diagnosed or disease-modifying treatment-naïve *SF3B1*^{mut} or *SF3B1*^{wt} MDS patients (experimental cohort: Supplementary Table S1; Fig. S1) and healthy donors (HD) to identify genotype-immunophenotype correlations. Initial gene expression profiling of 730 immune-related genes in *SF3B1*^{mut} versus *SF3B1*^{wt} MDS BM mononuclear cells (BM-MNCs) revealed a predominantly myeloid cell-related innate immune gene signature (e.g., *CYBB*, *CSF1R*)


lacking signs of overt myeloid-driven inflammation (i.e. *IL1B*, *CXCL5*), whereas lymphoid-related genes were underrepresented (e.g., *CD3D*, *CD79A*) (Supplementary Table S4, Fig. S2). These results are consistent with the reported lower proportion of lymphocytes in BM [8], mild myeloid dysplasia [9], and our previous finding of significantly lower *IL1B* mRNA in BM monocytes from *SF3B1*^{mut} LR-MDS [10]. As IL-1β protein levels in paired BM plasma samples were often below the detection limit, we could not determine whether lower mRNA levels correspond to lower cytokine levels.

Next, we conducted high-dimensional mass cytometry (CyTOF) on BM-MNCs and analyzed data using the Tracking Responders EXpanding (T-REX) algorithm to identify immunophenotypic differences associated with LR-MDS and *SF3B1*^{K700E} LR-MDS in particular. As expected, LR-MDS (*SF3B1*^{mut} and *SF3B1*^{wt}) showed several immunophenotypic changes consistent with an activated immune response (Fig. 1A, Supplementary Fig. S3/S4), in particular specific clusters resembling terminally differentiated effector memory CD8⁺ T cells (T_{TE}/TEMRA, cluster 1295), mature CD57⁺ NK cells (cluster 2495), CD27⁺ IgD[−] memory B cells (cluster 795), and γδ T cells with an exhausted immunophenotype (cluster 1395). LR-MDS exhibited dysregulated T-cell homeostasis, with fewer naïve CD4⁺ and CD8⁺ T cells, and memory phenotype skewing toward CD8⁺ effector memory (T_{EM}) and T_{TE} cells (Supplementary Fig. S4). This is consistent with progressive memory differentiation entailing loss of survival, which could contribute to impaired long-term antitumor immunosurveillance.

¹Department of Internal Medicine I, University Hospital Carl Gustav Carus, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany. ²Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University of Leipzig Medical Center, Leipzig, Germany. ³Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. ⁴IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. ⁵MDS Unit, Hematology, AOU Careggi - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. ⁶Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), AOU Careggi, Florence, Italy. ⁷Laboratory of Systems Tumor Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg, and Universitätsklinikum Erlangen, Erlangen, Germany. ⁸Deutsches Zentrum Immuntherapie und Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. ⁹Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy. ¹⁰Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany. ¹¹National Center for Tumor Diseases (NCT); German Cancer Research Center (DKFZ); Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. ¹²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. ¹³German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁴German MDS Study Group (D-MDS), Leipzig, Germany. ¹⁵Haematology Department, Guy's Hospital, London, UK. ¹⁶These authors contributed equally: Susann Winter, Marie Schneider, Uwe Platzbecker, Shahram Kordasti. ✉email: shahram.kordasti@kcl.ac.uk

Received: 29 November 2023 Revised: 27 March 2024 Accepted: 8 April 2024

Published online: 17 April 2024



We then compared *SF3B1*^{K700E} to *SF3B1*^{wt} LR-MDS using the T-REX pipeline, which identified a *SF3B1*^{K700E}-specific cluster comprising CD33⁺ CD14⁺ monocytes (cluster 495, $p < 0.01$) (Fig. 1B, Supplementary Fig. S5). Further analysis of CD33⁺ CD14⁺ BM-MNCs showed

that a remarkable proportion of the monocytes in *SF3B1*^{K700E} LR-MDS adopt a HLA-DR^{low/neg} phenotype (Fig. 1C). Importantly, retrospective analysis of diagnostic flow cytometry data (Fig. 1D–E) and external validation in two independent cohorts comprising combined 130

Fig. 1 Monocytes with HLA-DR^{low/neg} immunophenotype emerge frequently in the BM of *SF3B1*^{mut} MDS. **A** T-REX plot of regions of significant change on Uniform Manifold Approximation (UMAP) axes for CD45⁺ BM-MNCs stained for CyTOF showing distinct LR-MDS-specific (dark red, ≥95% of cells are contributed by LR-MDS samples) and HD-specific (dark blue, ≥95% of cells are contributed by HD) cell clusters. 14 LR-MDS (mean age = 74 years, 4 women, 10 men) and 4 HD (mean age = 58 years, all men) were included in the analysis. LR-MDS group comprises *SF3B1*^{K700E} (*n* = 5, orange dots; mean age = 75 years, 2 women, 3 men) and *SF3B1*^{wt} (*n* = 9, blue dots; mean age = 74 years, 2 women, 7 men) patients. Top 10 Marker Enrichment Modeling (MEM) labels with enrichment scores are shown for statistically significant LR-MDS-specific clusters (cutoff >2000 cells) indicated on T-REX plot. **B** T-REX analysis of CD45⁺ BM-MNCs stained for CyTOF showing distinct *SF3B1*^{K700E}-specific (dark red) and *SF3B1*^{wt}-specific (dark blue) cell clusters. Top 10 MEM labels are shown for statistically significant and trend clusters (cutoff >1000 cells) indicated on T-REX plot. **A, B** Labels on T-REX plot indicate major immune cell subsets (myeloid cells, NK cells, $\gamma\delta$ T cells, CD4⁺ and CD8⁺ T cells, B cells). **C** T-REX analysis of CD33⁺ CD14⁺ pre-gated monocytes showing *SF3B1*^{K700E}-specific (dark red) and *SF3B1*^{wt}-specific (dark blue) clusters. Cluster 795 depicts a distinct HLA-DR^{low/neg} monocyte subset in *SF3B1*^{K700E} LR-MDS (NOTE: this cluster is not related to cluster 795 shown in (A)). HLA-DR expression was projected onto UMAP axes. **A–C** Two-sided Mann–Whitney–U-test/Wilcoxon rank-sum test was performed for indicated clusters (*p* < 0.05 was considered significant; *p*-values are shown in brackets). Box plots depict median, IQR (lower and upper hinges), and 1.5 times the IQR (lower and upper whiskers extend to values within 1.5 times the IQR from the hinge). **(D)** Percentage of CD33⁺ CD14⁺ BM monocytes with HLA-DR^{low/neg} immunophenotype in HD (median = 9.7, IQR = 8 [*n* = 9, mean age = 69 years, 6 women, 3 men]), *SF3B1*^{mut} (median = 37.9, IQR = 34.9 [*n* = 17; orange dots, K700E; light orange-filled circles, nonK700E including one K666R, one E622D, one H662Y, and one Y623C; mean age = 71 years, 6 women, 11 men]), and *SF3B1*^{wt} (median = 6.3, IQR = 11.2 [*n* = 16, mean age = 66 years, 8 women, 8 men]) MDS assessed by diagnostic FCM of freshly stained BM samples (Kruskal–Wallis test with Dunn's post-hoc test [Bonferroni adjusted *p*-values]). **E** Representative HLA-DR staining on CD33⁺ CD14⁺ BM monocytes. The black line indicates the set threshold distinguishing low or negative from high HLA-DR expression. **F** Percentage of CD33⁺ CD14⁺ BM monocytes with HLA-DR^{low/neg} immunophenotype in four *SF3B1*^{K700E} MDS patients over time. Patients #4, #10, and #11 harbor an isolated *SF3B1*^{K700E} mutation.

MDS (118 LR-MDS) patients (Supplementary Fig. S6) confirmed an increased frequency of HLA-DR^{low/neg} monocytes in *SF3B1*^{mut} (both *SF3B1*^{K700E} and *SF3B1*^{nonK700E}) compared to *SF3B1*^{wt} MDS and HD. The external data support our observation that staining cryopreserved BM-MNCs may underestimate the actual frequency of HLA-DR^{low/neg} monocytes. Additionally, we found a strong correlation between HLA-DR^{low/neg} monocyte frequencies in BM and PB (Supplementary Fig. S7). HLA-DR^{low/neg} monocytes in *SF3B1*^{mut} MDS were classical monocytes (CM) based on the lack of CD16 surface expression (Supplementary Fig. S7). Analysis of longitudinal data from four *SF3B1*^{K700E} MDS patients showed a consistently high frequency of HLA-DR^{low/neg} monocytes (Fig. 1F).

To the best of our knowledge, the only other study directly investigating immunophenotypic features in BM of *SF3B1*^{mut} MDS reported lower expression of CD11b, CD36, and CD64 on monocytes [8]. Another study found a higher frequency of thrombomodulin-expressing CM in MDS subtypes with <5% blasts and RS [11]. The association of *SF3B1* mutations with lower monocyte surface HLA-DR expression identified here may be of clinical relevance, for example in view of the predicted poor response of *SF3B1*^{mut} MDS to IST [6, 7]. Overall, the frequency of HLA-DR^{low/neg} monocytes showed no correlation with blood hemoglobin levels, the Revised International Prognostic Scoring System (IPSS-R) risk classifications, or the mutational burden of *SF3B1* and co-mutated *TET2* or *DNMT3A* (Supplementary Fig. S7). HLA-DR^{low/neg} monocyte frequencies were comparable between transfusion-dependent and -independent *SF3B1*^{mut} LR-MDS (Supplementary Fig. S6). However, HLA-DR^{low/neg} monocytes have known immunoregulatory properties via multiple mechanisms, including effector T-cell inhibition, decreased antigen presentation, and defective dendritic cell maturation [12]. A possible scenario is that the early acquisition of *SF3B1* mutations [13] and the presence of inflammation foster the emergence of HLA-DR^{low/neg} monocytes, which then contribute to counteract and balance inflammatory responses in established *SF3B1*^{mut} MDS. In this context, T-REX also identified a cluster of naïve CD4⁺ T cells specific to *SF3B1*^{K700E} LR-MDS with low expression of the co-stimulatory molecule CD27 (cluster 3895, MEM score CD27⁺¹) (Fig. 1B, Supplementary Fig. S4/S5). Thus, although disease-related shifts in CD4⁺/CD8⁺ T-cell differentiation were noticeable irrespective of *SF3B1* mutation status, naïve CD4⁺ T cells in *SF3B1*^{K700E} LR-MDS displayed subtle immunophenotypic differences indicative of less recent activation.

As CD14⁺ monocytes lose HLA-DR expression, they become functionally deactivated, which can contribute to the transition to a more immunosuppressed state. To investigate whether this is the case for CM from *SF3B1*^{K700E} LR-MDS, we studied their global gene

expression profile using RNA-seq. Overall, we found 545 up- and 812 downregulated genes in the clonally involved CM from *SF3B1*^{K700E} LR-MDS compared to HD (Supplementary Table S5). Importantly, these patients harbored an isolated K700E mutation and no confounding cytogenetic aberrations. Upregulated genes were enriched in genes involved in oxygen transport (e.g., *HBB*, *HBA1/2*), probably due to erythrocyte impurities or enhanced phagocytosis of damaged erythrocytes by CM in *SF3B1*^{K700E} LR-MDS. Downregulated genes were significantly enriched in genes related to cytokine signaling, including cytokine receptors (e.g., *IL6R*, *IL10RA*, *IL7R*, *TNFRSF1A*), *TREM1*, signaling kinases (e.g., *MAP3K7*, *MAP3K8*, *PIK3CG*), and NF- κ B signaling modulators (e.g., *NFKB1B*, *IKBK*, *RELA/B*) (Fig. 2A). Ingenuity pathway analysis (IPA) of DEG identified enriched pathways pertaining to inflammatory cytokine signaling (i.e. NF- κ B signaling, IL-6 signaling, acute phase response signaling, PI3K/AKT signaling) and inflammatory conditions (i.e. hepatic fibrosis signaling pathway) that could be affected in *SF3B1*^{K700E} CM (Fig. 2B). Expression levels of the NF- κ B targets *IL1B* and *TNF* were, however, variable between individual patients (Supplementary Fig. S8). Notably, IPA-based analysis of DEG in CM from *SF3B1*^{wt} LR-MDS patients, of whom 2 out of 3 carried somatic mutations in *TET2*, brought to the fore different inflammatory pathways predicted to be more active compared to HD (Fig. 2B).

In addition, we analyzed alternative splicing in *SF3B1*^{K700E} versus HD CM using rMATS (Supplementary Table S6). Among the more robust differentially spliced genes (DSG) were various genes previously reported as mis-spliced in *SF3B1*^{mut} cells, such as *BRD9*, *COASY*, and *TMEM214* (Fig. 2C, Supplementary Table S6). We could also confirm the previously reported cryptic 3' splice site for *MAP3K7* predicted to undergo nonsense-mediated RNA decay [14], along with decreased *MAP3K7* transcript levels in *SF3B1*^{K700E} CM (Supplementary Fig. S9, Table S5). We did not observe a clear association of the longer *IRAK4* isoform with *SF3B1*^{K700E} (Supplementary Fig. S9), as has been reported previously [15]. DSG were enriched in genes involved in the regulation of defense response and cytokine signaling, next to mRNA metabolism, apoptotic signaling, and mitotic cell cycle (Fig. 2C, Supplementary Table S7). Importantly, 369 out of the 834 DSG were also differentially spliced in *SF3B1*^{K700E} versus *SF3B1*^{wt} LR-MDS CM (Supplementary Table S8).

Based on the RNA-seq data pointing to dysregulated cytokine signaling in *SF3B1*^{K700E} CM, we then assessed their cytokine secretion following in vitro stimulation with the Toll-like receptor 4 agonist lipopolysaccharide (LPS). We found that CM with a heterozygous mutation in *SF3B1* (VAF ~ 0.4) responded to LPS stimulation with adequate secretion of pro- (TNF, IL-1 β , IL-6, IP-10, MCP-1) and anti-inflammatory cytokines (IL-10, IL-1RA) (Fig. 2D), except for one patient with an extremely high mutation burden (VAF = 0.86) (Fig. 2D). This




Fig. 2 Classical monocytes (CM) from $SF3B1^{K700E}$ LR-MDS exhibit dysregulated immune gene expression and splicing. **A Metascape pathway and process enrichment analysis of up- and downregulated genes in peripheral blood CM from $SF3B1^{K700E}$ LR-MDS ($n = 3$) compared to HD ($n = 3$). The top 10 and 20 representative terms are shown for up- and downregulated genes, respectively. **B** IPA core pathway analysis showing the predicted activity (cutoff z-score of $>|0.5|$) of overrepresented annotations (p -value < 0.05 [right-tailed Fisher's exact test]) based on the list of DEG (PostFC ≥ 2 or ≤ 0.5 , PPDE > 0.95) in $SF3B1^{K700E}$ or $SF3B1^{wt}$ compared to HD CM ($n = 3$ per group). **C** Alternative splicing (AS) signature in $SF3B1^{K700E}$ CM: Volcano plot highlighting differentially spliced genes (DSG) with inclusion level difference (ILD) $> |0.2|$ and pie chart showing distribution of differential splicing event types detectable in $SF3B1^{K700E}$ LR-MDS compared to HD CM using rMATS. Shown below is the pathway and process enrichment analysis of DSG using Metascape (top 20 enriched terms across input DSG). **D** Cytokine secretion of LPS-stimulated CM was determined by Luminex analysis. Heatmap depicts Log2-transformed normalized median fluorescence intensity values for the indicated cytokines produced by HD, $SF3B1^{K700E}$, or $SF3B1^{wt}$ ($n = 3$ per group) LR-MDS classical monocytes following in vitro LPS stimulation. The variant allele frequency (VAF) of $SF3B1^{K700E}$ mutation in CM is shown on the left side. AS alternative splicing, A3SS alternative 3' splice site, A5SS alternative 5' splice site, DEG differentially expressed genes, DSG differentially spliced genes, MXE mutually exclusive exon, RI retained intron, SE skipped exon.**

patient exhibited the highest basal mRNA levels of *TNF* and *IL-6* (Supplementary Fig. S8), which only marginally increased with LPS stimulation. Altogether, at the level of secreted cytokines, we did not observe markedly hyperactivated NF- κ B signaling in $SF3B1^{K700E}$ CM following LPS exposure, although we can confirm mis-splicing and reduced mRNA expression of *MAP3K7*, previously linked to enhanced

NF- κ B activity [14]. In interpreting our findings, it is important to acknowledge the small sample size for functional assays as a limitation of our study. Therefore, further research with larger sample sizes will be required to address the functional and stimulation context-dependent deficits resulting from mis-splicing of the identified genes.

Phenotypically, the HLA-DR^{low/neg} CM resemble monocytic myeloid-derived suppressor cells (M-MDSCs), but markers associated with M-MDSC biology were not enriched in SF3B1^{K700E} CM (Supplementary Fig. S8). However, HLA-DR^{low/neg} CM from one SF3B1^{K700E} LR-MDS patient with co-mutations in *TET2* and *DNMT3A* had a less stimulatory effect on the proliferative capability of autologous CD4⁺ T cells compared to their HLA-DR^{high} counterparts (Supplementary Fig. S10). In light of this, the conversion to HLA-DR^{low/neg} CM may prevent excessive inflammatory reactions in the tissue driven partly by disproportionate T-cell activation. Further studies comparing HLA-DR^{low/neg} and HLA-DR^{high} CM from patients with an isolated SF3B1^{K700E} mutation will help to clarify their respective roles in the inflammation process.

DATA AVAILABILITY

RNA-seq data are publicly available at GEO under accession number GSE236535.

REFERENCES

- Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, et al. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. *Leukemia*. 2022;36:2894–902.
- Lieu YK, Liu Z, Ali AM, Wei X, Penson A, Zhang J, et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. *Proc Natl Acad Sci USA*. 2022;119:e2111703119.
- Clough CA, Pangallo J, Sarchi M, Ilagan JO, North K, Bergantinos R, et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. *Blood*. 2022;139:2038–49.
- Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, et al. SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. *Blood*. 2017;130:881–90.
- Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. *Lancet Oncol*. 2017;18:1338–47.
- Stahl M, DeVeaux M, De Witte T, Neukirchen J, Sekeres MA, Brunner AM, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Adv*. 2018;2:1765–72.
- Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, et al. SF3B1 mutations negatively predict for response to immunosuppressive therapy in myelodysplastic syndromes. *Clin Lymphoma Myeloma Leuk*. 2020;20:400–406.e2.
- Duetz C, Westers TM, in 't Hout FEM, Cremers EMP, Alhan C, Venniker-Punt B, et al. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype. *Br J Haematol*. 2021;193:798–803.
- Malcovati L, Stevenson K, Papaemmanuil E, Neuberger D, Bejar R, Boultonwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood*. 2020;136:157–70.
- Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M, et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. *Leukemia*. 2023;37:1709–18.
- van Leeuwen-Kerkhoff N, Westers TM, Poddighe PJ, de Grijijl TD, Kordasti S, van de Loosdrecht AA. Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation. *Haematologica*. 2020;105:961–70.
- Mengos AE, Gastineau DA, Gustafson MP. The CD14+HLA-DrIo/NEG monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy. *Front Immunol*. 2019;10:1147.
- Todisco G, Moura PL, Hellström-Lindberg E. Clinical manifestations of clonal hematopoiesis: what has SF3B1-mutant MDS taught us? *Semin Hematol*. 2022;59:150–5.
- Lee SCW, North K, Kim E, Jang E, Obeng E, Lu SX, et al. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. *Cancer Cell*. 2018;34:225–241.e8.
- Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. *Elife*. 2022;11:e78136.

ACKNOWLEDGEMENTS

We would like to thank Ivonne Habermann (University Hospital Carl Gustav Carus, Dresden, Germany) for excellent technical support and all technicians in the flow

cytometry laboratories for processing samples and acquiring raw data. We would also like to thank Dr. Sebastian Stasik (Department of Internal Medicine I, University Hospital Carl Gustav Carus, Faculty of Medicine, TU Dresden, Dresden, Germany) for help with variant calling from RNA-seq data, Caroline E. Roe (Mass Cytometry Center of Excellence, Vanderbilt University, Nashville, TN, USA) for help with the T-REX pipeline, and Dr. Falk Heidenreich (Department of Internal Medicine I, University Hospital Carl Gustav Carus, Faculty of Medicine, TU Dresden) for constructive feedback and discussions. Moreover, we would like to thank Dr. Jörg Lehmann and Claudia Müller for providing and assisting with the FLEXMAP 3D™ system (Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany). We also thank the King's College London research facilities and the University College London/Department of Computer Science HPC facility for support. We would also like to thank all the patients for contributing to this study. This work was supported by the transCampus funding program between King's College London and TU Dresden (UP), the DTK partner site Dresden (UP), the European Union - Transcan 7 Horizon 2020 - EuroMDS project #20180424 (MGDP), the Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (MGDP), and the AIRC Foundation (Associazione Italiana per la Ricerca contro il Cancro, Milan, Italy) projects #22053 (to MGDP) and #26537 (to VS). SK and RADR are supported by the CRUK City of London Centre Award [CTRQR-2021/100004] at KCL.

AUTHOR CONTRIBUTIONS

SW, MSchn, UO, GM, ER, MGR, SB, BP, DC, RADR, JAT, NS, and AT contributed to the collection of data. UO analyzed clinical FCM data of the experimental cohort. ER, MGR, SB, and BP analyzed FCM data of the validation cohorts. DC performed bioinformatics analysis of NanoString and RNA-seq data. EG and CL analyzed and visualized RNA-seq data. SW and MSchn analyzed and visualized data. SW, MSchn, JV, KS, AP, MGDP, VS, MSchn, and SK interpreted the results. UP and SK designed the project. UP and KS recruited MDS patients and contributed to clinical care. SW and SK conceptualized the work and wrote and edited the manuscript. All authors were involved in the review of the work and approval of the final version of the manuscript.

COMPETING INTERESTS

SW, MS, UO, GM, ER, MGR, SB, BP, DC, RADR, EG, CL, JV, JT, NS, KS, AP, AT, MGDP, VS, MS, and UP declare no competing financial interests. SK has received research support and honoraria from Novartis (advisory board, speakers bureau), Alexion (speakers bureau), Beckman Coulter (speakers bureau), MorphoSys (research support), and Pfizer (speakers bureau). None of these are relevant to the current work.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-024-02249-z>.

Correspondence and requests for materials should be addressed to Shahram Kordasti.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024